

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 11

**Complete if Known**

Application Number

Filing Date

First Named Inventor

Group Art Unit

Examiner Name

Attorney Docket Number

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
	1	US- 6056954	05/02/00	Fischetti, et al.	
	2	US- 5997862	12/07/99	Fischetti, et al.	
	3	US- 5985271	11/16/99	Fischetti, et al.	
	4	US- 5688501	11/18/97	Merril, et al.	
	5	US- 4742981	05/10/88	Converse	
	6	US- 2019789	11/05/35	Mahannah	
	7	US- 2763931	09/25/56	McMillan	
	8	US- 5479732	01/02/96	Burtch, et al.	
	9	US- 3465445	09/09/69	Fisher	
	10	US- 2315260	03/30/43	Lancaster	
	11	US- 5604109	02/18/97	Fischetti, et al.	
	12	US- 5260292	11/09/93	Robinson, et al.	
	13	US- 4957686	09/18/90	Norris	
	14	US- 6017528	01/25/00	Fischetti, et al.	
	15	US- 6132970	10/17/00	Stemmer	
	16	US- 3852424	12/03/74	Gaeumann, et al.	
	17	US- 6264945	07/24/01	Fischetti, et al.	
	18	US- 6254866	07/03/01	Fischetti, et al.	
	19	US- 6248324	06/19/01	Fischetti, et al.	
	20	US- 6238661	05/29/01	Fischetti, et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	21	EP-0510907 A 2	10/28/92	Agricultural & Food Res.		
	22	WO-9702351	01/23/97	CIBA Geigy AG, et al.		
	23	WO-9607329	03/14/96	Univ. Maryland		
	24	WO-9904809	02/04/99	Ambi, Inc.		
	25	FR-2357246	02/03/78	Martinez		
	26	WO-9531562	11/23/95	Quest International B.V.		
	27	EP-587541 A1	03/16/94	Tecnogen ScpA		

Examiner  
SignatureDate  
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 11

**Complete if Known**

Application Number

Filing Date

First Named Inventor

Group Art Unit

Examiner Name

Attorney Docket Number

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
	28	US- 6056955	05/02/00	Fischetti, et al.	
	29	US- 5882631	03/16/99	Suga, et al.	
	30	US- 5741487	04/21/98	Asai, et al.	
	31	US- 6113887	09/05/00	Mori, et al.	
	32	US- 4122158	10/24/78	Schmitt	
	33	US- 3983209	09/28/76	Schmitt	
	34	US- 4885163	12/05/89	Shaar, et al.	
	35	US- 6177554	01/23/01	Woo, et al.	
	36	US- 6187757	02/13/01	Clackson, et al.	
	37	US- 5162226	11/10/92	Beachey, et al.	
	38	US- 6335012	01/01/02	Fischetti, et al.	
	39	US- 6326002	12/04/01	Fischetti, et al.	
	40	US- 6277399	08/21/01	Fischetti, et al.	
	41	US- 4062941	12/13/77	Davies	
	42	US- 5571667	11/05/96	Chu, et al.	
	43	US- 5514602	05/07/96	Brooks Jr, et al.	
	44	US- 5500350	03/19/96	Baker, et al.	
	45	US- 5384265	01/24/95	Kidwell, et al.	
	46	US- 4361537	11/30/82	Deutsch, et al.	
	47	US- 5120643	06/09/92	Ching, et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	48	WO-9323544	11/25/93	The University Court of the University of Glasgow		
	49	EP-0293249 A1	11/30/88	Amrad Corporation Limited		
	50	EP-0646646 A2	04/05/95	Bristol-Myers Squibb Company		
	51	EP-0359873 A1	03/28/90	The Public Health Research Inst. of the City of New York		

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <div style="text-align: center; font-weight: bold; font-size: 1.2em;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</div> <div style="text-align: center; font-style: italic; font-size: 0.8em;">(use as many sheets as necessary)</div>		<div style="text-align: right; font-weight: bold; font-size: 0.9em;">Complete if Known</div> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr><td style="width: 60%; padding: 2px;">Application Number</td><td style="width: 40%;"></td></tr> <tr><td style="padding: 2px;">Filing Date</td><td></td></tr> <tr><td style="padding: 2px;">First Named Inventor</td><td></td></tr> <tr><td style="padding: 2px;">Group Art Unit</td><td></td></tr> <tr><td style="padding: 2px;">Examiner Name</td><td></td></tr> <tr><td style="padding: 2px;">Attorney Docket Number</td><td></td></tr> </table>		Application Number		Filing Date		First Named Inventor		Group Art Unit		Examiner Name		Attorney Docket Number	
Application Number															
Filing Date															
First Named Inventor															
Group Art Unit															
Examiner Name															
Attorney Docket Number															
Sheet	3	of	11												

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
	52	US-4948726	08/14/90	Longoria	
	53	US- 4459361	07/10/84	Gefter	
	54	US- 4552839	11/12/85	Gould, et al.	
	55	US- 4313734	02/02/82	Leuversing	
	56	US- 4847199	07/11/89	Snyder, et al.	
	57	US- 4497900	02/05/85	Abram, et al.	
	58	US- 4707543	11/17/87	Zollinger, et al.	
	59	US- 5763251	06/09/98	Gasson	
	60	US- 6159688	12/12/00	Borchert, et al.	
	61	US- 4784948	11/15/88	Scott, et al.	
	62	US- 5760026	06/02/98	Blackburn, et al.	
	63	US- 5602040	02/11/97	May, et al.	
	64	US- 4521252	06/04/85	Miyake, et al.	
	65	US- 4355022	10/19/82	Rabussay	
	66	US- 4115546	09/19/78	Vidra, et al.	
	67	US- 4116327	09/26/78	Eglinton, et al.	
	68	US- 3929994	12/30/75	Hirsch, et al.	
	69	US- 6083684	07/04/00	Gasson	
	70	US- 5360617	11/01/94	Gasson	
	71	US- 5079174	01/07/92	Buck, et al.	

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<b><i>Complete if Known</i></b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				Application Number	
				Filing Date	
				First Named Inventor	
				Group Art Unit	
				Examiner Name	
				Attorney Docket Number	
Sheet	4	of	11		

[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

5

of

11

**Complete if Known**

Application Number

Filing Date

First Named Inventor

Group Art Unit

Examiner Name

Attorney Docket Number

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	82	KH Nasibulini et al; RU-2103991; Composition for treating streptococcal diseases - comprises purified concentrate of streptococcal bacteriophage, solution of quinosol, dry lanolin, albumin and vegetable oil; XP-002141110	
	83	LD Demidova et al; RU2064299; Cattle mastitis therapeutic preparation - comprises lyso: amidase of specific lytic activity and mono- and di-basic sodium phosphate(s); XP-002141111	

Examiner  
Signature

Date

Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	
				Filing Date	
				First Named Inventor	
				Group Art Unit	
				Examiner Name	
Sheet	6	of	11	Attorney Docket Number	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	84	BABENKO et al. Enzymatic lysis of staphylococci in relation to their species and strain properties, 1990, Database Medline Online, US National Library of Medicine, Bethesda, MD, US, Database Accession No. 90297672 XP002170795, abstract only	
	85	BARTELL, et al., Origin of polysaccharide depolymerase associated with bacteriophage infection, Journal of Virology, March 1969, pp. 290-296, Vol. 3, No. 3	
	86	BEHNKE, et al., Cloning and expression in Escherichia coli, Bacillus subtilis and Streptococcus sanguis of a gene for staphylokinase - a bacterial plasminogen activator, Mol Gen Genet, December 1987, pp. 528-534, Vol. 210	
	87	BESSEN, et al., Chemical characterization of binding properties of opacity-associated protein II from Neisseria gonorrhoeae, Infection and Immunity, January 1987, pp. 141-147, Vol. 55, No. 1	
	88	BIZIULEVICHUS, et al., In vivo studies on lysosubtilin: 3. Efficacy for treatment of mastitis and superficial lesions of the udder and teats in cows, 1998, Database Biosis Online, Biosciences Information Service, Philadelphia, PA, US, Database Accession No. PREV199800492606, XP002183274, abstract only	
	89	BOIZET, et al., Cloning, expression and sequence analysis of an endolysin-encoding gene of Lactobacillus bulgaricus bacteriophage mv1, Gene, 2000, pp. 61-67, Vol. 94	
	90	CALDWELL, et al., Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis, Infection and Immunity, March 1981, pp. 1161-1176, Vol. 31, No. 3	
	91	YOUNG et al. Phages will out: strategies of host cell lysis, Trends in Microbiology, Volume 8 No. 3, March 2000, pp 120-127	
	92	CORBEL, et al., Soluble antigens obtained from influenza virus by treatment with non-ionic detergent, J Hyg., Camb., 1970, pp. 81-96, Vol. 68	
	93	CROUX, et al., Interchange of functional domains switches enzymes specificity: construction of a chimeric pneumococcal-clostridial cell wall lytic enzyme, Molecular Microbiology, 1993, pp.1019-25, Vol. 9, No. 5	
	94	DIAZ, et al., Chimeric phage-bacterial enzymes: a clue to the modular evolution of genes, Proc. Natl. Acad. Sci. USA, October 1990, pp. 8125-8129, Vol. 87	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	
				Filing Date	
				First Named Inventor	
				Group Art Unit	
				Examiner Name	
Sheet	7	of	11	Attorney Docket Number	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	95	DIAZ, et al., Chimeric pneumococcal cell wall lytic enzymes reveal important physiological and evolutionary traits, Journal of Biological Chemistry, March 25, 1991, pp. 5464-5471, Vol. 266, No. 9	
	96	DIXON, et al., Lysostaphin: an enzymatic approach to staphylococcal disease. III. Combined lysostaphin-methicillin therapy of established staphylococcal abscesses in mice, The Yale Journal of Biology and Medicine, August 1968, pp. 62-68, Vol. 41, No. 1	
	97	FISCHETTI, et al., Size variation of the M protein in group A streptococci, Journal of Exp. Med., June 1, 1985, pp. 1384-1401, Vol. 161, No. 6	
	98	GARCIA, et al., Bacteriophages of Streptococcus pneumoniae: A molecular approach, Microbial Drug Resistance, Summer 1997, pp. 165-176, Vol. 3, No. 2	
	99	GARCIA, et al., Cloning, purification and biochemical characterization of the pneumococcal bacteriophage Cp-1 lysin, Journal of Virology, August 1987, pp. 2573-2580, Vol. 61, No. 8	
	100	GARCIA, et al., Modular organization of the lytic enzymes of streptococcus pneumoniae and its bacteriophages, Gene, 1990, pp. 81-88, Vol. 86	
	101	GERARDY-SCHANN, et al., Molecular cloning and functional expression of bacteriophage PK1E-encoded endoneuraminidase Endo NE, Molecular Microbiology, May 1995, pp. 441-450, Vol. 16, No. 3	
	102	GOLDBERG, et al., Studies in experimental staphylococcal endocarditis in dogs, Antimicrobial Agents and Chemotherapy, 1967, pp. 45-53	
	103	HARRISON, et al., Lysostaphin in experimental renal infections, Journal of Bacteriology, February 1967, pp. 520-524, Vol. 93, No. 2	
	104	HARRISON, et al., Therapeutic activity of lysostaphin in experimental staphylococcal infections, Canadian Journal of Microbiology, January 1967, pp. 93-97, Vol. 13, No. 1	
	105	HAYASHI, et al., Effects of N-Acetylmuramidase from Streptomyces rutgersensis H-46 as a food preservative, Agric. Biol. Chem., December 1989, pp. 3173-3177, Vol. 53, No. 12	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	
				Filing Date	
				First Named Inventor	
				Group Art Unit	
				Examiner Name	
Sheet	8	of	11	Attorney Docket Number	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	106	HAYASHIDA, et al., Further characterization of PL-1 phage associated N-acetylmuramidase of Lactobacillus casei, Journal of General Microbiology, May 1987, pp. 1343-1349, Vol. 133, No. 5	
	107	HIGUCHI, et al., Transfection of streptococcus sanguis by phage deoxyribonucleic acid isolated from streptococcus mutans, Infection and Immunity, March 1977, pp. 945-949, Vol. 15, part 3	
	108	HUAN, et al., Methicillin-resistant staphylococcus aureus infection and its treatment in burned patients, Chinese Journal of Surgery, 1994, Vol. 32, No. 4, abstract	
	109	HUGHEY, et al., Antimicrobial activity of lysozyme against bacteria involved in food spoilage and food-borne disease, Applied and Environmental Microbiology, September 1987, pp. 2165-2170, Vol. 53, No. 9	
	110	KOHLER, Systemic therapy with aerosols Aerosols in Medicine: Principles, Diagnosis and Therapy, 1993, Elsevier Science Publishers, pp. 303-319	
	111	LAWMAN, et al., Molecular cloning of the extracellular endodextranase of streptococcus salivarius, Journal of Bacteriology, December 1991, pp. 7423-7428, Vol. 173, No. 23	
	112	LOESSNER, et al., Evidence for a holin-like protein gene fully embedded out of frame in the endolysin gene of staphylococcus aureus bacteriophage 187, Journal of Bacteriology, August 1999, pp. 4452-4460, Vol. 181, No. 15	
	113	LOESSNER, et al., Modified listeria bacteriophage lysis genes (ply) allow efficient overexpression and one - step purification of biochemically active fusion proteins, Applied and Environmental Microbiology, August 1996, pp. 3057-3060, Vol. 62, No. 8	
	114	LOPEZ, et al., Architecture and domain interchange of the pneumococcal cell wall lytic enzymes, Genetics of Streptococci, Enterococci and Lactococci, Developments in Biological Standardization, 1995, pp. 273-281, Vol. 85	
	115	LOPEZ, et al., The pneumococcal cell wall degrading enzymes a modular design to create new lysins, Microbial Drug Resistance, November 2, 1997, pp. 199-211, Vol. 3, No. 2	
	116	MARTIN, et al., Functional analysis of the two-gene lysis system of the pneumococcal phage Cp-1 in homologous and heterologous host cells, Journal of Bacteriology, January 1998, pp. 210-217, Vol. 180, No. 2	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 9 of 11

**Complete if Known**

Application Number	
Filing Date	
First Named Inventor	
Group Art Unit	
Examiner Name	
Attorney Docket Number	

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	117	MUKHLIS, et al., Characterization and Immunogenicity of HSV-1 antigens obtained following zwitterionic detergent treatment; Vaccine, September 1986, pp. 191-196, Vol. 4	
	118	NELSON, et al., Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme, PNAS, March 27, 2001, pp. 4107-4112, Vol. 98, No. 7	
	119	NELSON, et al., Selective and rapid killing of group A streptococci using a muralytic enzyme, Database Biosis Online, Biosciences Information Service, Philadelphia, PA, US and abstracts of the General Meeting of the American Society for Microbiology, 2000, pp. 32-33	
	120	OKI, et al., Functional and structural features of the holin HOL protein of the Lactobacillus plantarum phage analysis in escherichia coli system, Gene, 1997, pp. 137-145, Vol. 197	
	121	OKUHARA, et al., Preparation of group A streptococcal cell membranes by treatment with group C streptococcus phage - associated lysin, Annales Paediatrici Japonici, June 1983, pp. 10-19, Vol. 29, No. 2	
	122	PATTON, et al., Routes of delivery: case studies, Pulmonary delivery of peptides and proteins for systemic action, Advanced Drug Delivery Reviews, 1992, pp. 179-196, Vol. 8	
	123	POLAK, et al., In vitro activity of recombinant lysostaphin-antibiotic combinations toward methicillin-resistant staphylococcus aureus, Diagn. Microbiol. Infect. Dis., 1993, pp. 265-270, Vol. 17	
	124	RAINA, Purification of streptococcus group C bacteriophage lysin, Journal of Bacteriology, January 1981, pp. 661-663, Vol. 145, No. 1	
	125	RONDA, et al., Infection of streptococcus oralis NCTC 11427 by pneumococcal phages, FEMS Microbiology Letters, 1989, pp. 187-192, Vol. 65	
	126	SANZ, et al., Construction of a multifunctional pneumococcal murein hydrolase by module assembly, Eur. J. Biochem., February 1, 1996, pp. 601-605, Vol. 235, No. 3	
	127	SATO, et al., Partial characterization of n - Butanol - solubilized rejection - type antigens of syngeneic murine colon tumors, JNCI, April 1985, Vol. 74, No. 4	

Examiner  
SignatureDate  
Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 10 of 11

**Complete if Known**

Application Number

Filing Date

First Named Inventor

Group Art Unit

Examiner Name

Attorney Docket Number

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	128	SHEEHAN, et al., Analysis of the catylytic domain of the lysin of the lactococcal bacteriophage Tuc2009 by chimeric gene assembling; FEMS Microbiology Letters, 1996, pp. 23-28, Vol. 140	
	129	SHEEHAN, et al., The lytic enzyme of the pneumococcal phage Dp-1: A chimeric lysin of intergeneric origin, Molecular Microbiology, 1997, pp. 717-725	
	130	WITTE, et al., Characterization of escherichia coli lysis using a family of chimeric E-L genes, FEMS Microbiology Letters, 1998, pp. 159-167, Vol. 164	
	131	YARNALL, et al., Isolation and partial characterization of a type II Fc receptor from a group A streptococcus, Molecular and Cellular Biochemistry, 1986, pp. 57-66, Vol. 70	
	132	CISANI, et al., High-level potentiation of lysostaphin anti-staphylococcal activity by lysozyme, Antimicrobial Agents and Chemotherapy, April 1982, pp. 531-535, Vol.21, No. 4	

Examiner  
SignatureDate  
Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

+

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**Complete if Known**

Sheet

11

of

11

Application Number

Filing Date

First Named Inventor

**Group Art Unit**

Examiner Name

Attorney Docket Number

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
	133	US-5605793	02/25/97	Stemmer	
	134	US- 6355477	03/12/02	Fischetti et al	
	135	US- 6331405	12/18/01	Rambukkana et al	
	136	US- 6190659	02/20/01	Pancholi et al	
	137	US- 5985654	11/16/99	Fischetti et al	
	138	US- 5842314	11/24/98	Scott et al	
	139	US- 5910441	06/08/99	Rocha et al	
	140	US- 5786205	07/28/98	Fischetti et al	
	141	US- 5976792	11/02/99	Cheung et al	
	142	US- 5821088	10/13/98	Darzins et al	
	143	US- 5723303	03/03/98	Fischetti et al	
	144	US- 5643767	07/01/97	Fischetti et al	
	145	US- 5707822	01/13/98	Fischetti et al	
	146	US- 5616686	04/01/97	Fischetti et al	
	147	US- 5604109	02/18/97	Fischetti et al	
	148	US- 5587288	12/24/96	Cheung et al	
	149	US- 5556944	09/17/96	Fischetti et al	
	150	US- 5352588	10/04/94	Fischetti et al	
	151	US- 5968763	10/19/99	Fischetti et al	
	152	US- 4784948	11/15/88	Scott et al	

[illegible]

**Examiner  
Signature**

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

+